FATE vs CDNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 02, 2026
FATE
CDNA
Investment Advisor Scores
CDNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | FATE | CDNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 156.25 | Tie |
| PEG Ratio | 0 | -0.12 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 9.2% | 52.2% | CDNA |
| Earnings Growth | 0.0% | 0.0% | Tie |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 41.6/100 | 32.0/100 | FATE |
| Profit Margin | 0.0% | 24.2% | CDNA |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | AVOID NEW MONEY | FATE |
Relative Price Performance (Last 90 Days)
Current Technical Phase
FATE
MarkdownPrice below a falling SMA50 (slope -5.5%), weak momentum, RSI 40
CDNA
MarkupPrice above SMA50, rising 50-day trend (24.9% over 20 days), RSI 82
Fundamentals Snapshot
| Metric | FATE | CDNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -2.4 | 51.3 |
| Trailing P/E | — | 30.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.5% |
| Gross Margin | -12.0% | 0.7% |
| Operating Margin | -15.0% | 0.0% |
| EPS | -1.05 | 2.11 |
| Dividend Yield | — | — |